Velzatinib obtains ODD in Japan for GIST treatment

AI SummaryClose X

GSK announced velzatinib received Orphan Drug Designation in Japan, adding to existing US and EU ODDs and US FDA Fast Track designation; the ODD was supported by StrateGIST 1 data showing promising anti-tumour activity and tolerability. Phase III trials in first- and second-line advanced/metastatic GIST have been accelerated, with second-line enrolment tracking ahead of schedule and pivotal data expected in H2 2027. Seven abstracts on velzatinib will be presented at CTOS 2026. Velzatinib targets all clinically relevant KIT mutations in a market of ~80,000–120,000 annual GIST patients globally, where ~80% have KIT-driven disease and ~90% develop secondary KIT mutations; Japan incidence ≈4 per 100,000.

Disclaimer*

Companies

GSK (GSK)
UK 100

Latest directors dealings